Cell mediated and humoral immune response of chickens to live infectious bronchitis vaccines

Timms, L.M.; Bracewell, CD

doi:10.1016/s0034-5288(18)32492-5

Cited by 14 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reason that cross-protection occurs has never been fully explained. A cell-mediated immunity (CMI) response after initial vaccination with the H120 strain was observed (Timms & Bracewell, 1981) and that response was observed to be cross-reactive (Dhinakar Raj & Jones, 1997). It was shown that the H strain had a rare ability to cross-protect against serotypes which are heterologous making it potentially effective in the control of a broader range of serotypes (Bijlenga et al, 2004).…”

Section: Discussionmentioning

confidence: 99%

Protection of chickens vaccinated with combinations of commercial live infectious bronchitis vaccines containing Massachusetts, Dutch and QX-like serotypes against challenge with virulent infectious bronchitis viruses 793B and IS/1494/06 Israel variant 2

Bru¹,

Vila²,

Cabana³

et al. 2016

Avian Pathology

View full text Add to dashboard Cite

Infectious bronchitis virus (IBV) is a coronavirus which affects chickens of all ages. IBV mainly causes respiratory disease but can also result in reduced weight gain, reduced egg production, increased frequency of abnormal eggs and increased rates of mortality. Vaccination is the most important way to control the disease. Nevertheless, novel strains of infectious bronchitis (IB) continue to emerge in the field. In order to respond promptly, combinations of existing IB vaccines are frequently tested to see whether they can provide cross-protection. The efficacy of a combination of vaccines based on Massachusetts, Dutch and QX-like IB strains against emerging IB Israel variant 2 and IB 793B strains was assessed by means of four challenge studies. At least 80% of the birds vaccinated with IB H120 (Mass type) combined with IB D274 (Dutch type) followed by a QX-like IB vaccine booster or vaccinated with a combination of IB H120, IB D274 and QX-like IB were protected against a challenge with IB 793B. In addition, IB 1263 (Mass type) boosted by QX-like IB showed an 85% protection following challenge with IB 793B. A combination of IB H120 and IB D274 boosted by QX-like IB vaccine conferred 70% protection whilst H120 and IB D274 combination on its own showed 61.1% protection against Israel variant 2 challenge. IB 1263 boosted by a QX-like IB vaccine showed 50% protection against IB Israel variant 2. Therefore, it can be concluded that a combination of the IB H120, IB D274 and QX-like IB confers broad protection against different non-related virulent IB strains.

show abstract

Section: Discussionmentioning

confidence: 99%

Protection of chickens vaccinated with combinations of commercial live infectious bronchitis vaccines containing Massachusetts, Dutch and QX-like serotypes against challenge with virulent infectious bronchitis viruses 793B and IS/1494/06 Israel variant 2

Bru¹,

Vila²,

Cabana³

et al. 2016

Avian Pathology

View full text Add to dashboard Cite

show abstract

“…Reports concerning a role for cell-mediated immunity in protection against IBV are limited. Antigen-specific proliferation of T-lymphocytes in IBV-infected or vaccinated chickens has been demonstrated (Timms et al, 1980;Timms & Bracewell, 1981, 1983. In some chickens, a positive correlation between lymphoproliferative responses and resistance to challenge has been shown (Timms & Bracewell, 1981).…”

Section: Cellular Immunitymentioning

confidence: 98%

Infectious bronchitis virus: Immunopathogenesis of infection in the chicken

1997

View full text Add to dashboard Cite

SUMMARYThe immunopathogenesis of infectious bronchitis virus (IBV) infection in the chicken is reviewed. While infectious bronchitis (IB) is considered primarily a disease of the respiratory system, different IBV strains may show variable tissue tropisms and also affect the oviduct and the kidneys, with serious consequences. Some strains replicate in the intestine but apparently without pathological changes. Pectoral myopathy has been associated with an important recent variant. Several factors can influence the course of infection with IBV, including the age, breed and nutrition of the chicken, the environment and intercurrent infection with other infectious agents. Immunogenic components of the virus include the S (spike) proteins and the N nucleoprotein. The humoral, local and cellular responses of the chicken to IBV are reviewed, together with genetic resistance of the chicken. In long-term persistence of IBV, the caecal tonsil or kidney have been proposed as the sites of persistence. Antigenic variation among IBV strains is related to relatively small differences in amino acid sequences in the S1 spike protein. However, antigenic studies alone do not adequately define immunological relationships between strains and cross-immunisation studies have been used to classify IBV isolates into 'protectotypes'. It has been speculated that changes in the S1 protein may be related to differences in tissue tropisms shown by different strains. Perhaps in the future, new strains of IBV may arise which affect organs or systems not normally associated with IB.

show abstract

“…The N-gene specific protein response is associated with the induction of CTLs that are responsible for clearance of IBV-infected cells [ 34 , 67 ]. The CTLs response peaked after 10 days, correlating with a decrease in clinical signs and viral clearance from lungs [ 68 ]. A significant increase in the CD4+ and CD8+ T-cells has been reported following vaccination with S1-gene specific IBV vaccines; thus S1-gene importantly plays role in cell-mediated immune response [ 69 ].…”

Section: Host Immune Response Against Infectious Bronchitis Virusmentioning

confidence: 99%

Progress and Challenges toward the Development of Vaccines against Avian Infectious Bronchitis

Bande

Arshad

Bejo

et al. 2015

Journal of Immunology Research

140

122

View full text Add to dashboard Cite

Avian infectious bronchitis (IB) is a widely distributed poultry disease that has huge economic impact on poultry industry. The continuous emergence of new IBV genotypes and lack of cross protection among different IBV genotypes have been an important challenge. Although live attenuated IB vaccines remarkably induce potent immune response, the potential risk of reversion to virulence, neutralization by the maternal antibodies, and recombination and mutation events are important concern on their usage. On the other hand, inactivated vaccines induce a weaker immune response and may require multiple dosing and/or the use of adjuvants that probably have potential safety risks and increased economic burdens. Consequently, alternative IB vaccines are widely sought. Recent advances in recombinant DNA technology have resulted in experimental IB vaccines that show promise in antibody and T-cells responses, comparable to live attenuated vaccines. Recombinant DNA vaccines have also been enhanced to target multiple serotypes and their efficacy has been improved using delivery vectors, nanoadjuvants, and in ovo vaccination approaches. Although most recombinant IB DNA vaccines are yet to be licensed, it is expected that these types of vaccines may hold sway as future vaccines for inducing a cross protection against multiple IBV serotypes.

show abstract

Cell mediated and humoral immune response of chickens to live infectious bronchitis vaccines

Cited by 14 publications

References 13 publications

Protection of chickens vaccinated with combinations of commercial live infectious bronchitis vaccines containing Massachusetts, Dutch and QX-like serotypes against challenge with virulent infectious bronchitis viruses 793B and IS/1494/06 Israel variant 2

Protection of chickens vaccinated with combinations of commercial live infectious bronchitis vaccines containing Massachusetts, Dutch and QX-like serotypes against challenge with virulent infectious bronchitis viruses 793B and IS/1494/06 Israel variant 2

Infectious bronchitis virus: Immunopathogenesis of infection in the chicken

Progress and Challenges toward the Development of Vaccines against Avian Infectious Bronchitis

Contact Info

Product

Resources

About